{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:48:11Z","timestamp":1790412491243,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20306"],"award-info":[{"award-number":["DB-2020C2-20306"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112910","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:12:58Z","timestamp":1758575578000},"page":"112910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3857-9445","authenticated-orcid":false,"given":"Stacey M.","family":"Sklepinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6841-7706","authenticated-orcid":false,"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-3622","authenticated-orcid":false,"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan J.","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.diabres.2025.112910_b0005","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diab Care"},{"issue":"9","key":"10.1016\/j.diabres.2025.112910_b0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.diabres.2025.112910_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307451","article-title":"Trends in diabetes medication prescribing from 2018 to 2021: a cross-sectional analysis","volume":"19","author":"Riad","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.diabres.2025.112910_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110841","article-title":"Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: a retrospective database study (DEFINE-G)","volume":"203","author":"Ohsugi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"23","key":"10.1016\/j.diabres.2025.112910_b0025","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","article-title":"Trends in diabetes treatment and control in U.S. adults, 1999-2018","volume":"384","author":"Fang","year":"2021","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.diabres.2025.112910_b0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.diabres.2025.112910_b0035","doi-asserted-by":"crossref","unstructured":"Neumiller JJ, Herrin J, Swarna KS, et al. Kidney outcomes with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas in type 2 diabetes and moderate cardiovascular risk. Clin J Am Soc Nephrol. Published online October 8, 2024. doi:10.2215\/CJN.0000000587.","DOI":"10.2215\/CJN.0000000587"},{"issue":"10193","key":"10.1016\/j.diabres.2025.112910_b0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.diabres.2025.112910_b0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.112910_b0050","doi-asserted-by":"crossref","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. Published online March 29, 2025. doi:10.1056\/NEJMoa2501006.","DOI":"10.1056\/NEJMoa2501006"},{"issue":"19","key":"10.1016\/j.diabres.2025.112910_b0055","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.diabres.2025.112910_b0060","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112910_b0065","unstructured":"GlaxoSmithKline UK Ltd. GlaxoSmithKline Safety Advisory: Reminder letter regarding the discontinuation of Eperzan (albiglutide). Published online July 1, 2018. Accessed February 11, 2025. https:\/\/assets.publishing.service.gov.uk\/media\/5b4c89c5ed915d436ea7ea8b\/Eperzan-25062018.pdf."},{"issue":"25","key":"10.1016\/j.diabres.2025.112910_b0070","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038568","article-title":"Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"103","author":"Kamrul-Hasan","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.diabres.2025.112910_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator intype2diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"issue":"7","key":"10.1016\/j.diabres.2025.112910_b0080","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.diabres.2025.112910_b0085","unstructured":"Polley, E, LeDell, E, Kennedy, C, Lendle, S, van der Laan, M. SuperLearner: Super Learner Prediction. Published online 2021. Accessed October 4, 2023. https:\/\/CRAN.R-project.org\/package=SuperLearner."},{"key":"10.1016\/j.diabres.2025.112910_b0090","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112910_b0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"17","key":"10.1016\/j.diabres.2025.112910_b0100","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.diabres.2025.112910_b0105","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112910_b0110","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1214\/20-EJS1740","article-title":"Correcting an estimator of a multivariate monotone function with isotonic regression","volume":"14","author":"Westling","year":"2020","journal-title":"Electron J Stat"},{"issue":"3","key":"10.1016\/j.diabres.2025.112910_b0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2025.112910_b0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"13","key":"10.1016\/j.diabres.2025.112910_b0125","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.diabres.2025.112910_b0130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2025.112910_b0135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112910_b0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112910_b0145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112910_b0150","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/dom.15529","article-title":"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression","volume":"26","author":"Rivera","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"10.1016\/j.diabres.2025.112910_b0155","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1161\/CIRCULATIONAHA.119.043353","article-title":"Exploring the possible impact of unbalanced open-label drop-in of glucose-lowering medications on EXSCEL outcomes","volume":"141","author":"Bethel","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.diabres.2025.112910_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004431","article-title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA","volume":"12","author":"King","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabres.2025.112910_b0165","unstructured":"U.S. Food and Drug Administration. FDA Drug Shortages. Accessed February 11, 2025. https:\/\/dps.fda.gov\/drugshortages."},{"issue":"2","key":"10.1016\/j.diabres.2025.112910_b0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"Compounded GLP-1 and dual GIP\/GLP-1 receptor agonists: a statement from the American diabetes association","volume":"48","author":"Neumiller","year":"2025","journal-title":"Diab Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:42:34Z","timestamp":1773135754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S0168822725009246"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112910","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112910"}}